Literature DB >> 28594442

Body mass index and risk of gastric cancer: A 30-year follow-up study in the Linxian general population trial cohort.

Jin-Hu Fan1, Jian-Bing Wang2, Shao-Ming Wang1, Christian C Abnet3, You-Lin Qiao1, Philip R Taylor4.   

Abstract

Although a number of previous studies have noted either positive or no association for body mass index (BMI) and gastric cancer risk, little evidence exists in the Chinese population. We prospectively examined the associations of BMI with risk of gastric cancer in the Linxian General Population Trial cohort, with 29 584 healthy adults enrolled in 1985 and followed through to the end of 2014. Body weight and height were measured during physical examination at baseline and BMI was calculated as weight in kilograms divided by height in meters squared. Body mass index from 138 subjects was missing, and a total of 29 446 participants were included in the final analysis. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. During 30 years of follow-up, we confirmed 1716 newly diagnosed gastric cardia adenocarcinoma (GCA) cases and 626 new gastric non-cardia adenocarcinoma (GNCA) cases. Overall, compared to the lowest quartile (BMI <20.32 kg/m2 ), subjects in the fourth quartile (BMI ≥23.31 kg/m2 ) subjects had lower risk of developing GNCA (hazard ratio, 0.65; 95% confidence interval, 0.51-0.83). Age- and sex-specific analyses showed that this protective effect was only observed in men and older (52 + years) persons. No associations were observed for BMI with GCA incidence. Higher BMI was associated with decreased risk of GNCA in this population, particularly in men and older persons. Future studies are needed to confirm these findings. The trial is registered with ClinicalTrials.gov: NCT00342654.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  Body mass index; Linxian general population trial cohort; gastric cardia adenocarcinoma; gastric non-cardia adenocarcinoma; prospective study

Mesh:

Year:  2017        PMID: 28594442      PMCID: PMC5543512          DOI: 10.1111/cas.13292

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


Gastric cancer is a major health concern and ranked as the third leading cause of cancer death worldwide in 2012, causing an estimated 723 000 deaths.1 Nearly 45% of the world's gastric cancers occur in China.1 Within Lin County (Linxian) and the surrounding Taihang Mountain region in north central China, rates of upper gastrointestinal cancers are particularly high and account for over 20% of all deaths. Over the past few decades, several risk factors for gastric cancer have been identified, including Helicobacter pylori infection,2 smoking,3 alcohol use,4 and micronutrient deficiency.5 Despite abundant epidemiological studies focused on the association between excess body weight and risk of gastric cancer, results have been inconclusive.6, 7, 8, 9, 10, 11, 12 A number of studies showed increased risk for obesity6, 7, 8, 9, 10, 11 while others suggested no risk.12 Prospective cohort6, 8 and case–control9, 13, 14 studies found obesity was associated with risk of gastric cardia adenocarcinoma (GCA), but not with gastric non‐cardia adenocarcinoma (GNCA). Most studies of body size and gastric cancer were undertaken in populations from Europe and North America where obesity is particularly common. It is still unknown whether the findings of these studies can be extrapolated to Asian populations. The present study examined the associations between body mass index (BMI) and risk of GCA and GNCA in the Linxian general population trial cohort in China.

Materials and Methods

Study population

Detailed information on the Linxian general population trial cohort has been reported in previous studies.15, 16 Briefly, the general population trial enrolled individuals from the general population of four communes in northern Linxian. Potential participants were eligible if they were between the ages of 40 and 69 years, lived in one of the four communes, and provided written informed consent. A total of 29 584 healthy adults were randomized and received one of eight daily vitamin/mineral supplement combinations according to a one‐half replicate of a 24 fractional factorial design for 5.25 years, beginning in March 1986.

Data collection

Data on demographic characteristics and lifestyle factors were obtained using a standard questionnaire at baseline. All participants had their weight and height measured by trained staff. Body weight and height were measured while subjects were not wearing shoes, using a standard protocol. Body mass index was then calculated as weight in kilograms divided by height in meters squared. Smoking (including ever or current smokers) was defined as regular cigarette or pipe use for at least 6 months, and alcohol use was defined as any alcohol consumption in the past 12 months. Family history of any cancer was considered positive if a cancer was reported in at least one‐first‐degree relative. We also collected information on previous chronic disease at baseline including heart disease, stroke, cirrhosis, and diabetes mellitus.

Follow‐up for cancer

During the trial period (1986–1991), village doctors visited all participants monthly, and all end‐points were confirmed by an International End‐points Review Committee consisting of American and Chinese experts in cytology, pathology, surgery, and radiology. During the post‐trial follow‐up periods (after 1991), village doctors continued to visit all participants monthly, and new cancer cases and deaths were verified by a panel of Chinese experts. All gastric cardia cancers were adenocarcinomas that occurred in the proximal 3 cm of the stomach and the gastroesophageal junction, and gastric non‐cardia cancers were adenocarcinomas located more distally.

Statistical analysis

Body mass index was divided into four categories based on quartiles: <20.32, ≥20.32 to <21.76, ≥21.76 to <23.31, and ≥23.31. International standard categories for BMI (<18.5, 18.5–25.0, 25.0–30.0, and ≥30.0) were used in sensitivity analyses. Participants were censored at their last known follow‐up date, date of death, or December 31, 2014, whichever occurred first. Frequency and percentage for demographic characteristics were calculated by BMI category. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for associations between baseline BMI and risk of GCA and GNCA. Crude and adjusted HRs were estimated using participants with a BMI <20.32 kg/m2 as the reference group. Potential confounders included age at baseline (continuous variable), sex (male or female), smoking (yes or no), alcohol use (yes or no), education (never, less than 5 years, primary school, tertiary high school or higher education, others), and family history of cancer (positive defined as cancer in at least one‐first‐degree relative or negative). Subgroup analyses were carried out by age at baseline (<52 or ≥52 years, based on the median age of members of the cohort at baseline), sex (male or female), smoking (yes or no), drinking (yes or no), and family history of cancer (yes or no). Sensitivity analyses were also undertaken by excluding subjects who were smokers or drinkers or patients with pre‐existing chronic disease or were followed up for less than 3 years. To address the possibility of residual confounding by measured variables, we further adjusted for a propensity score that reflected associations of BMI with the other variables in the Cox regression model. The shape of the association between BMI and risk of gastric cancer was explored using BMI as a continuous variable in the Cox proportional hazards regression models. We also fit continuous models with the addition of a square term to investigate possible non‐linear associations. All statistical analyses were carried out using SAS software (version 9.2; SAS Institute, Cary, NC, USA). All tests were two‐sided and associations were considered significant for P‐values less than 0.05.

Ethical approval

This study was approved by the Institutional Review Boards of the US NIH and the Chinese Academy of Medical Science. All participants gave written informed consent for the use of their blood samples and all data.

Results

A total of 29 446 individuals were included in the final analysis. During 583 070 person‐years of follow‐up, we identified 1716 incident GCA cases and 626 GNCA cases, and approximately 1% of participants were lost to follow‐up. Compared with the lowest quartile (BMI <20.32), subjects with BMI ≥23.31 were younger (51.1 vs 53.7 years), more often women (64.7% vs 57.0%), more educated (higher education, 9.3% vs 7.4%), more often alcohol users (22.1% vs 20.9%), and less commonly smokers (21.2% vs 31.5%). Among the variables examined, significant differences between quartiles of BMI were observed for age at baseline, sex, smoking, alcohol drinking, education, and family history of cancer (Table 1).
Table 1

Baseline demographic characteristics by body mass index (BMI) in the Linxian general population trial cohort

BMI
Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)
No. of participants, n (%)7267 (24.68)7530 (25.57)7304 (24.80)7345 (24.94)
Person‐years135 276.91149 170.89149 526.21149 095.76
Age, years, mean ± SD53.67 ± 8.8151.74 ± 8.8650.96 ± 8.7851.09 ± 8.75
Sex, n (%)
Men3122 (42.96)3876 (51.47)3535 (48.40)2594 (35.32)
Women4145 (57.04)3654 (48.53)3769 (51.60)4751 (64.68)
Education level, n (%)
Never3304 (45.47)2734 (36.31)2670 (36.56)3098 (42.18)
Less than 5 years2186 (30.08)2530 (33.60)2418 (33.11)2054 (27.96)
Primary school634 (8.72)859 (11.41)883 (12.09)772 (10.51)
Tertiary high school or higher education536 (7.38)766 (10.17)719 (9.84)684 (9.31)
Others607 (8.35)641 (8.51)614 (8.41)737 (10.03)
Smoking, n (%)
No4977 (68.49)4827 (64.10)4958 (67.88)5791 (78.84)
Yes2290 (31.51)2703 (35.90)2346 (32.12)1554 (21.16)
Alcohol drinking, n (%)
No5748 (79.10)5614 (74.56)5449 (74.60)5721 (77.89)
Yes1519 (20.90)1916 (25.44)1855 (25.40)1624 (22.11)
Family history of cancer, n (%)
No4834 (66.52)4988 (66.24)4741 (64.91)4748 (64.64)
Yes2433 (33.48)2542 (33.76)2563 (35.09)2597 (35.36)
BMI, kg/m2, mean ± SD19.13 ± 0.9921.06 ± 0.4122.48 ± 0.4525.22 ± 1.81

Q, quartile.

Baseline demographic characteristics by body mass index (BMI) in the Linxian general population trial cohort Q, quartile. Table 2 presents associations between BMI and risk of GCA and GNCA. No associations were observed for BMI and risk of GCA. In contrast, persons with BMI ≥23.31 were at reduced risk of GNCA (HR, 0.65; 95% CI, 0.51–0.83) compared with the lowest quartile (BMI <20.32). No association with GNCA risk was seen for persons in the other two BMI categories. When we used the WHO/National Heart, Lung, and Blood Institute criteria, with a BMI of 18.5–25.0 as a reference, no associations were seen for GCA risk, but HRs for GNCA were 0.99 (95% CI, 0.68–1.42) for BMI <18.5, 0.66 (0.47–0.92) for BMI 25.0–30.0, and 0.43 (0.06–3.04) for BMI ≥30.0 (Table S1). Cumulative incidence rates of GCA and GNCA were significantly different by BMI categories using WHO/National Heart, Lung, and Blood Institute criteria (Figs. S1,S2).
Table 2

Crude and adjusted hazards ratios (HRs) and 95% confidence intervals (CIs) for the associations between body mass index (BMI) and gastric cardia adenocarcinoma (GCA) and gastric non‐cardia adenocarcinoma (GNCA) in the Linxian general population trial cohort

Body mass index, kg/m2
Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)
GCA
No. of cases403481442390
Crude HR (95% CI)1.00 1.08 (0.95–1.23) 0.99 (0.86–1.13) 0.87 (0.76–1.00)
Age‐ and sex‐adjusted HR (95% CI)1.00 1.07 (0.93–1.22) 1.02 (0.89–1.17) 1.00 (0.87–1.45)
Multivariate adjusted HR (95% CI)a 1.00 1.07 (0.94–1.22) 1.02 (0.89–1.17) 1.01 (0.88–1.16)
GNCA
No. of cases170199154103
Crude HR (95% CI)1.00 1.07 (0.87–1.31) 0.82 (0.66–1.02) 0.55 (0.43–0.70)
Age‐ and sex‐adjusted HR (95% CI)1.00 1.07 (0.87–1.32) 0.86 (0.69–1.07) 0.64 (0.50–0.82)
Multivariate adjusted HR (95% CI)a 1.00 1.07 (0.87–1.32) 0.86 (0.69–1.08) 0.65 (0.51–0.83)

Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. Q, quartile.

Crude and adjusted hazards ratios (HRs) and 95% confidence intervals (CIs) for the associations between body mass index (BMI) and gastric cardia adenocarcinoma (GCA) and gastric non‐cardia adenocarcinoma (GNCA) in the Linxian general population trial cohort Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. Q, quartile. In subgroup analyses (Table 3), no associations between BMI and GCA were observed in subgroups defined by either sex, age, smoking, drinking, or family history of cancer. However, risk of GNCA was reduced in men, older persons, non‐smokers, non‐drinkers, and individuals without family history of cancer. Compared with the lowest quartile, men with BMI ≥23.31 had an adjusted HR of 0.59 (95% CI, 0.42–0.82) for GNCA. Similarly, individuals aged ≥52 years with BMI ≥23.31 had an HR of 0.56 (95% CI, 0.38–0.83) compared with the lowest quartile. Results were similar across strata of smoking, drinking, and family history of cancer (all P‐values for interaction >0.05).
Table 3

Subgroup analyses for the associations between body mass index (BMI) and risk of gastric cardia adenocarcinoma (GCA) and gastric non‐cardia adenocarcinoma (GNCA) in the Linxian general population trial cohort

GCAGNCA
Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)
Sex
Men1.00 1.04 (0.88–1.23) 1.04 (0.88–1.23) 1.01 (0.84–1.22) 1.00 1.00 (0.78–1.30) 0.78 (0.59–1.03) 0.59 (0.42–0.82)
Women1.00 1.13 (0.91–1.41) 0.98 (0.79–1.23) 1.01 (0.81–1.24) 1.00 1.20 (0.85–1.70) 1.02 (0.71–1.46) 0.74 (0.51–1.08)
Age
<52 years1.00 1.21 (0.98–1.50) 1.17 (0.95–1.44) 1.16 (0.93–1.44) 1.00 1.23 (0.87–1.72) 1.02 (0.72–1.44) 0.87 (0.60–1.27)
≥52 years1.00 1.00 (0.84–1.18) 1.00 (0.78–1.12) 0.92 (0.76–1.11) 1.00 1.01 (0.77–1.31) 0.78 (0.58–1.05) 0.51 (0.36–0.72)
Smoking§
No1.00 1.13 (0.95–1.36) 0.99 (0.83–1.19) 1.01 (0.84–1.21) 1.00 1.20 (0.91–1.60) 0.98 (0.73–1.31) 0.68 (0.49–0.93)
Yes1.00 1.00 (0.82–1.22) 1.05 (0.86–1.29) 1.01 (0.80–1.27) 1.00 0.94 (0.70–1.27) 0.74 (0.53–1.03) 0.63 (0.43–0.95)
Drinking
No1.00 1.07 (0.91–1.24) 0.96 (0.82–1.13) 1.07 (0.91–1.26) 1.00 1.04 (0.82–1.32) 0.88 (0.68–1.31) 0.61 (0.46–0.82)
Yes1.00 1.07 (0.83–1.39) 1.17 (0.90–1.52) 0.83 (0.61–1.11) 1.00 1.16 (0.77–1.76) 0.83 (0.53–1.30) 0.77 (0.47–1.26)
Family history of cancer††
No1.00 0.77 (0.56–1.06) 1.04 (0.87–1.23) 1.12 (0.68–1.83) 1.00 1.04 (0.81–1.34) 0.82 (0.62–1.07) 0.56 (0.41–0.77)
Yes1.00 1.24 (0.89–1.73) 0.91 (0.73–1.14) 0.81 (0.40–1.63) 1.00 1.14 (0.80–1.63) 0.95 (0.66–1.38) 0.82 (0.55–1.23)

The bold entries are considered statistically significant. †Adjusted for age at baseline, smoking, drinking, family history of cancer, and education. ‡Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. §Adjusted for age at baseline, sex, drinking, family history of cancer, and education. ¶Adjusted for age at baseline, sex, smoking, family history of cancer, and education. ††Adjusted for age at baseline, sex, smoking, drinking, and education. Q, quartile.

Subgroup analyses for the associations between body mass index (BMI) and risk of gastric cardia adenocarcinoma (GCA) and gastric non‐cardia adenocarcinoma (GNCA) in the Linxian general population trial cohort The bold entries are considered statistically significant. †Adjusted for age at baseline, smoking, drinking, family history of cancer, and education. ‡Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. §Adjusted for age at baseline, sex, drinking, family history of cancer, and education. ¶Adjusted for age at baseline, sex, smoking, family history of cancer, and education. ††Adjusted for age at baseline, sex, smoking, drinking, and education. Q, quartile. Sensitivity analyses of exclusion subjects who were smokers or drinkers or had pre‐existing chronic diseases did not alter our results. We also undertook lag analyses stratified by duration of follow‐up, and results showed no effect on GCA risk, but indicated that the reduced risk of GNCA was limited to cases diagnosed 3 or more years after entry into the trial cohort, suggesting that this reduced risk was not due to pre‐existing disease. Further adjustment for propensity score for BMI in Cox models did not alter our findings (Table 4).
Table 4

Sensitivity analyses of the associations between body mass index (BMI) and risk of gastric cancer in the Linxian general population trial cohort

GCAGNCA
Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)Q1 (<20.32)Q2 (≥20.32 to <21.76)Q3 (≥21.76 to <23.31)Q4 (≥23.31)
All subjects
No. of cases403481442390170199154103
Multivariate HR (95% CI) 1.00 1.07 (0.94–1.22) 1.02 (0.89–1.17) 1.01 (0.88–1.16) 1.00 1.07 (0.87–1.32) 0.86 (0.69–1.08) 0.65 (0.51–0.83)
Exclude ever smokers
No. of cases228262238264881068967
Multivariate HR (95% CI) 1.00 1.13 (0.95–1.36) 0.99 (0.83–1.19) 1.01 (0.84–1.21) 1.00 1.20 (0.91–1.60) 0.98 (0.73–1.31) 0.68 (0.49–0.93)
Exclude ever drinkers
No. of cases30734430030913314111574
Multivariate HR (95% CI)§ 1.00 1.07 (0.91–1.24) 0.96 (0.82–1.13) 1.07 (0.91–1.26) 1.00 1.04 (0.82–1.32) 0.88 (0.68–1.31) 0.61 (0.46–0.82)
Exclude previous chronic disease
No. of cases393460429375163195143101
Multivariate HR (95% CI) 1.00 1.04 (0.91–1.20) 1.01 (0.88–1.16) 1.01 (0.87–1.16) 1.00 1.10 (0.89–1.35) 0.83 (0.66–1.05) 0.67 (0.52–0.87)
Exclude the first 3 years of follow‐up
No. of cases35242841135114517713592
Multivariate HR (95% CI) 1.00 1.07 (0.93–1.23) 1.06 (0.92–1.22) 1.02 (0.88–1.19) 1.00 1.09 (0.87–1.36) 0.86 (0.68–1.09) 0.66 (0.51–0.86)
Further adjust for intake of meat, eggs, vegetables and fruits
Multivariate HR (95% CI) 1.00 1.07 (0.94–1.22) 1.02 (0.89–1.17) 1.01 (0.88–1.16) 1.00 1.07 (0.87–1.32) 0.86 (0.69–1.07) 0.65 (0.51–0.83)
Adjust for propensity score for BMI
Multivariate HR (95% CI)†† 1.00 1.07 (0.94–1.22) 1.02 (0.89–1.17) 1.01 (0.88–1.16) 1.00 1.07 (0.87–1.32) 0.86 (0.69–1.08) 0.65 (0.51–0.83)

†Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. ‡Adjusted for age at baseline, sex, drinking, family history of cancer, and education. §Adjusted for age at baseline, sex, smoking, family history of cancer, and education. ¶Additional adjustment for dietary intake of meat, eggs, vegetables and fruits. ††Adjusted for propensity score for BMI. CI, confidence interval; GCA, gastric cardia adenocarcinoma; GNCA, gastric non‐cardia adenocarcinoma; HR, hazard ratio; Q, quartile.

Sensitivity analyses of the associations between body mass index (BMI) and risk of gastric cancer in the Linxian general population trial cohort †Adjusted for age at baseline, sex, smoking, drinking, family history of cancer, and education. ‡Adjusted for age at baseline, sex, drinking, family history of cancer, and education. §Adjusted for age at baseline, sex, smoking, family history of cancer, and education. ¶Additional adjustment for dietary intake of meat, eggs, vegetables and fruits. ††Adjusted for propensity score for BMI. CI, confidence interval; GCA, gastric cardia adenocarcinoma; GNCA, gastric non‐cardia adenocarcinoma; HR, hazard ratio; Q, quartile.

Discussion

This study prospectively examined the association between BMI categories and risk of gastric cancer in the Linxian general population trial cohort. In this prospective study, we found a significant association between higher BMI and lower risk of GNCA incidence. Compared with the lowest quartile, subjects with BMI ≥23.31 had a lower risk of GNCA, with an HR of 0.65 (95% CI, 0.51–0.83). Sensitivity analyses that excluded smokers or patients who had previous chronic disease did not affect our findings, and lag analyses did not suggest that pre‐existing disease could explain our results. Finally, no associations were observed for BMI and risk of GCA. Overweight and obesity are reportedly associated with risk of gastric cancer. However, it is still unclear whether overweight truly elevates the risk of gastric cancer. A number of meta‐analyses have revealed a positive association of BMI and risk of gastric cancer.10, 11, 12, 17, 18 The largest and most recent meta‐analysis to date,18 with a population of more than 10 million subjects from 24 prospective studies, showed that neither overweight nor obesity was associated with risk of total gastric cancer. Analyses restricted to Asian populations showed a borderline significant for overweight and risk of total gastric cancer. However, when gastric cancer was examined by anatomic subcategory, increased BMI was positively associated with risk of GCA (overweight: relative risk, 1.21; 95% CI, 1.03–1.42; obesity: relative risk, 1.82; 95% CI, 1.32–2.49), although no associations were seen with GNCA. Prospective cohort studies have suggested either a positive or no association for BMI and risk of gastric cancer.6, 7, 8, 19 The NIH‐AARP study,8 with a sample size of 218 854 participants, found a strong positive association for obesity and risk of GCA (HR, 3.67; 95% CI, 2.00–6.71). However, a population‐based cohort study in Norway with 73 133 participants showed no association for BMI and risk of gastric cancer.19 In our study, we did not find excess risk associated with higher BMI; instead, higher BMI was protective for risk of GNCA and unrelated to risk of GCA, consistent with an earlier analysis in the Linxian trial cohort.20 In this previous study, BMI was divided into four groups: <20 (reference), 20–21, 21–23, and ≥23, and an inverse association was observed for risk of GNCA among individuals with BMI ≥23 during 15 years of follow‐up (HR, 0.68; 95% CI, 0.49–0.93). The lack of association between BMI and risk of GCA is at odds with results from several previous studies. Discrepancies between our study and these previous studies could be due to the BMI categories evaluated, the referent group used, population differences, and/or differences in variables adjusted for in the analyses. Smoking or alcohol drinking is associated with BMI and an increased risk of gastric cancer, and can distort the association between BMI and risk of gastric cancer. We carefully adjusted our risk estimates for smoking and alcohol drinking, but model adjustment cannot fully address this confounding bias. Moreover, we excluded non‐smokers or non‐drinkers to perform a sensitivity analysis, and our results did not change. Additional adjustment of a propensity score that reflected associations of BMI with the other variables did not alter our findings. Reverse causality may be a great concern in evaluating the association of BMI with risk of gastric cancer. Participants with severe chronic disease such as cancer lose weight over time.21 In the current study, we collected information about cancer, heart disease, stroke, and diabetes at baseline, and excluded patients with these conditions as part of a sensitivity analysis, which did not alter our findings. We also carried out a lag analysis that showed that the protective effect of higher BMI was evident primarily, if not exclusively, in persons with three or more years of follow‐up, which suggests that our findings were not a consequence of pre‐existing disease. A hypothesis links obesity and risk of cancer through the action of three hormonal systems, including the insulin and insulin‐like growth factor axis, adipokines, and sex steroids.22, 23 These metabolic biomarkers are associated with obesity, and can help modulate cellular proliferation and apoptosis. Limited evidence from previous studies suggests that higher BMI seems to protect against the occurrence of GNCA. In our study, higher BMI had a protective effect on risk of GNCA. These findings could be explained by chance, and interpretations of our results should be very cautious. This study has several strengths, including its prospective design, long duration of follow‐up (30 years), measured (as opposed to self‐reported) BMI, the ability to exclude participants with previous chronic diseases, and the availability of information on numerous potential confounders. Our study also has several limitations. We only had a single measurement for BMI at baseline, which may have contributed to misclassification and did not permit an assessment of the weight change or rate of change. Recent studies reported that weight gain during adulthood was positively associated with risk of total or gastric cancers.7, 24 Second, esophageal adenocarcinoma and GCA are adjacent tumors, which are difficult to separate clinically. Bias due to this type of misclassification is almost certain to occur.25 However, the virtual absence of esophageal adenocarcinomas in Linxian makes this extremely unlikely.26 Furthermore, although we adjusted for many potential confounders, we cannot exclude the possibility of residual confounding due to unknown and unmeasured factors, such as H. pylori infection. As shown in previous studies, H. pylori infection is positively associated with risk of gastric cardia and non‐cardia cancers, but inversely associated with overweight/obesity. Our findings could be affected by the status of H. pylori infection, but we cannot assess this confounding bias due to lack of information at baseline. Finally, we cannot rule out the play of chance as an explanation for our results. Further studies are needed to address this issue. In conclusion, we found a significant association of higher BMI with lower risk of GNCA, but not with risk of GCA, in the Linxian general population trial cohort, even among cases occurring ≥3 years after baseline investigation. Additional studies are needed to confirm these findings in other Chinese populations.

Disclosure Statement

The authors have no conflict of interest. Table S1. Associations between body mass index (BMI) and gastric cardia and non‐cardia adenocarcinomas using WHO/National Heart, Lung, and Blood Institute criteria. Click here for additional data file. Fig. S1. Kaplan–Meier cumulative incidence for gastric cardia adenocarcinoma by body mass index (BMI) categories. Click here for additional data file. Fig. S2. Kaplan–Meier cumulative incidence for gastric non‐cardia adenocarcinoma by body mass index (BMI) categories. Click here for additional data file.
  26 in total

Review 1.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.

Authors:  Eugenia E Calle; Rudolf Kaaks
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

Review 2.  ABC of obesity. Obesity and cancer.

Authors:  Donald C McMillan; Naveed Sattar; Colin S McArdle
Journal:  BMJ       Date:  2006-11-25

3.  Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study.

Authors:  Krister Sjödahl; Yunxia Lu; Tom I L Nilsen; Weimin Ye; Kristian Hveem; Lars Vatten; Jesper Lagergren
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

Review 4.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.

Authors: 
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

5.  Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study.

Authors:  Audrey H H Merry; Leo J Schouten; R Alexandra Goldbohm; Piet A van den Brandt
Journal:  Gut       Date:  2007-03-02       Impact factor: 23.059

6.  Effect of body mass index on adenocarcinoma of gastric cardia.

Authors:  Ji Zhang; Xiang-Qian Su; Xiao-Jiang Wu; Ya-Hang Liu; Hua Wang; Xiang-Nong Zong; Yi Wang; Jia-Fu Ji
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

7.  Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China.

Authors:  Gina D Tran; Xiu-Di Sun; Christian C Abnet; Jin-Hu Fan; Sanford M Dawsey; Zhi-Wei Dong; Steven D Mark; You-Lin Qiao; Philip R Taylor
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

8.  Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates.

Authors:  Mats Lindblad; Weimin Ye; Anders Lindgren; Jesper Lagergren
Journal:  Ann Surg       Date:  2006-04       Impact factor: 12.969

9.  A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.

Authors:  Christian C Abnet; Neal D Freedman; Albert R Hollenbeck; Joseph F Fraumeni; Michael Leitzmann; Arthur Schatzkin
Journal:  Eur J Cancer       Date:  2008-01-24       Impact factor: 9.162

10.  Body mass and physical activity and risk of gastric cancer in a population-based cohort study in Norway.

Authors:  Krister Sjödahl; Chongqi Jia; Lars Vatten; Tom Nilsen; Kristian Hveem; Jesper Lagergren
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01-09       Impact factor: 4.254

View more
  5 in total

1.  Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study.

Authors:  Masahide Hamaguchi; Yoshitaka Hashimoto; Akihiro Obora; Takao Kojima; Michiaki Fukui
Journal:  BMJ Open Gastroenterol       Date:  2019-05-30

2.  Body Mass Index and Risk of Gastric Cancer in Asian Adults: A Meta-Epidemiological Meta-Analysis of Population-Based Cohort Studies.

Authors:  Jong-Myon Bae
Journal:  Cancer Res Treat       Date:  2019-08-12       Impact factor: 4.679

3.  Changes of Body Mass Index and Body Shape in relation to risk of Gastric Cancer: A population-based case-control study.

Authors:  Xiaolin Yin; Xiaorong Yang; Tongchao Zhang; Ziyu Yuan; Hui Chen; Li Jin; Xingdong Chen; Ming Lu; Weimin Ye
Journal:  J Cancer       Date:  2021-03-23       Impact factor: 4.207

4.  Body mass index and risk of upper gastrointestinal cancer: A 30-year follow-up of the Linxian dysplasia nutrition intervention trial cohort.

Authors:  Su Zhang; Jian-Bing Wang; Huan Yang; Jin-Hu Fan; You-Lin Qiao; Philip R Taylor
Journal:  Cancer Epidemiol       Date:  2020-02-09       Impact factor: 2.984

5.  Association between Body Mass Index and Gastric Cancer Risk According to Effect Modification by Helicobacter pylori Infection.

Authors:  Jieun Jang; Eun-Jung Cho; Yunji Hwang; Elisabete Weiderpass; Choonghyun Ahn; Jeoungbin Choi; Soung-Hoon Chang; Hai-Rim Shin; Min Kyung Lim; Keun-Young Yoo; Sue K Park
Journal:  Cancer Res Treat       Date:  2018-11-21       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.